PL.03: Plenary lecture
|
 |
 |
PL.03.01: René Hen - USA |
Harnessing hippocampal neurogenesis to improve cognition and mood |
PL.04: Plenary lecture
|
| |
|
PL.04.01: Arturas Petronis - Canada |
Epigenetics as a potential mechanism for intervention |
E.04: Educational update session: EPA educational update - Alcohol and suicidal risk
|
| |
|
E.04.02: Philip Gorwood - France |
Factors explaining suicidal behaviour and mortality in alcohol dependence |
| |
|
E.04.03: Gustavo Turecki - Canada |
Alcohol and suicidal risk: the epigenetic insight |
E.05: Educational update session: Refining designs of early drug trials to speed up decisions and registration
|
| |
|
E.05.01: J.M.A. Van Gerven - The Netherlands |
Innovative tools for 'proof-of-pharmacological-concept' studies |
| |
|
E.05.02: William Z. Potter - USA |
Making better early go/no-go decisions in drug development progress in the NIMH FAST-FAIL programme |
S.13: Symposium: Personalised treatment of major depression
|
| |
|
S.13.02: Brenda W.J.H. Penninx - The Netherlands |
Clinical and biological predictors of long-term course of major depressive disorder |
| |
|
S.13.03: Catherine Harmer - United Kingdom |
Early change in emotional processing as a predictor of treatment outcome with antidepressants or psychotherapy |
| |
|
S.13.04: Henricus G. Ruhe - The Netherlands |
fMRI markers for the prediction of short- and long-term outcome in major depressive disorder |
S.14: Symposium: New European pharma research initiatives
|
| |
|
S.14.01: Elisabetta Vaudano - Belgium |
IMI: Opportunities for researchers from IMI to Horizon 2020 |
| |
|
S.14.02: Will Spooren - Switzerland |
EU-AIMS: A trans-dimensional approach for enhancing our understanding of autism spectrum disorders |
| |
|
S.14.04: Jonathan Rabinowitz - Israel |
NewMeds: data sharing and new medications for depression and schizophrenia |
S.15: Symposium: Dysfunctional GABAergic networks in psychiatric disorders
|
| |
|
S.15.01: Imre Vida - Germany |
Functional consequences of GABAergic deficits: altered inhibition and oscillatory patterns in limbic networks |
| |
|
S.15.02: Rainer Rupprecht, M.D. - Germany |
Modulation of GABA-A receptor function for the treatment of anxiety disorders |
| |
|
S.15.03: Boldizsár Czéh - Hungary |
GABAergic dysfunctions in animal models for mood disorders |
S.16: Symposium: Anatomical diversity and functional differences in the dopaminergic and serotonergic system
|
| |
|
S.16.01: Christopher Lowry - USA |
Topographically organised serotonergic systems in the dorsal raphe play diverse roles in anxiety and depression |
| |
|
S.16.02: Mark Ungless - United Kingdom |
Dopamine neuron subgroups in the dorsal raphe and ventral tegmental area exhibit distinct synaptic adaptations in response to social isolation and drugs of abuse |
| |
|
S.16.03: Miriam Melis - Italy |
Subgroups of midbrain dopamine neurons exhibit discrete expression of endocannabinoid-mediated plasticity |
| |
|
S.16.04: Michael Van der Kooij - Switzerland |
Projection-specific roles of mesolimbic dopamine neurons: a focus on social competition and anxiety |
S.17: Symposium: TNM symposium – Unmet needs in paediatric psychopharmacology
|
| |
|
S.17.01: Antonio M. Persico - Italy |
Translational paediatric pharmacology |
| |
|
S.17.03: Benedetto Vitiello, M.D. - USA |
Should we expect smaller effect sizes in paediatric clinical trials? |
| |
|
S.17.04: Josefina Castro-Fornieles - Spain |
Pragmatic outcome assessment in clinical trials with children |
S.18: Symposium: New treatment strategies for schizophrenia
|
| |
|
S.18.01: Lieuwe de Haan - The Netherlands |
Low-dose and time-limited antipsychotic treatment strategies in schizophrenia |
| |
|
S.18.03: Robert W. Buchanan - USA |
Glutamatergic agents for the treatment of schizophrenia |
| |
|
S.18.04: Michael Davidson - Israel |
Nicotine receptor agonist treatment in schizophrenia |
S.19: Symposium: Biomarkers in bipolar disorder
|
| |
|
S.19.02: Iria Grande - Spain |
Neurotrophins, brain interconnectivity and neuronal survival in bipolar disorder |
| |
|
S.19.04: Colm McDonald - Ireland |
Neuroimaging deviations in bipolar disorder: genetic liability and structural disconnectivity |
S.20: Symposium: Adult neurogenesis in anxiety and mood disorders
|
| |
|
S.20.01: Djoher Nora Abrous - France |
Stress and adult hippocampal neurogenesis |
CD.04: Career development session:
Getting funded: European Research Council Starting Grant |
| |
|
Christof Kuhstoß - Germany |
|
